A recent trial showed no benefit of 1mg rasagiline versus placebo on 1-year progression in an early Parkinson’s disease cohort. The investigators used a novel method to track disease progression with MRI, apart from usual clinical standards. Dr. David Vaillancourt shares the results of this trial recently published in the Movement Disorders Journal. Read the article.